Meningitis and meningococcal septicaemia: Extended Review

Journal of the Royal College of Physicians of London

Volumn 32, Issue 4, 1998, Pages 319-328

  Pollard, Andrew J ^a   Faust, Saul N ^a   Levin, Michael ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTRIAXONE; MENINGOCOCCUS VACCINE; VANCOMYCIN;

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE TRANSMISSION; EARLY DIAGNOSIS; EMERGENCY MEDICINE; HUMAN; IMMUNITY; INTRACRANIAL PRESSURE; LABORATORY TEST; LUMBAR PUNCTURE; MENINGITIS; MENINGOCOCCOSIS; RASH; REVIEW; SEPTICEMIA; UNITED KINGDOM; VACCINATION;

BACTEREMIA; DIAGNOSIS, DIFFERENTIAL; GREAT BRITAIN; HUMANS; MENINGITIS, BACTERIAL;

EID: 0031711488     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Communicable Diseases Surveillance Centre. Notifications of infectious diseases. Commun Dis Rep 1998;8:17-20.
2. Office for National Statistics. 1994 Communicable Disease Statistics. Series MB2, No. 21, 1996.
3. Platt MJ. Child health statistical review. Arch Dis Child 1997;77:542-8.
4. Office for National Statistics. 1995 Communicable Disease Statistics. Series MB2, No. 22, 1997.
5. Office for National Statistics. 1995 Mortality statistics: childhood, infant and perinatal. Series DH3, No. 28, 1997.
6. Office for National Statistics. 1995 Mortality statistics: cause. Series DH2, No. 22, 1997.
7. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr 1981;99: 540-5.
8. Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 1996;15:967-7.
9. Ramsay M, Kaczmarski E, Rush M, Mallard R, et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep 1997;7:R49-54.
10. Havens PL, Garland JS, Brook MM, Dewitz BA, et al. Trends in mortality in children hospitalised with meningococcal infections, 1957 to 1987. Pediatr Infect Dis J 1989;8:8-11.
11. Marzouk O, Thomson APJ, Sills JA, Hart CA, Harris F. Features and outcome in meningococcal disease presenting with maculopapular rash. Arch Dis Child 1991;66:485-7.
12. Pollard AJ, De Munter C, Nadel S, Levin M. Abandoning empirical antibiotics for febrile children. Lancet 1997;350:811-2.
13. Barnes RA, Jenkins P, Coakley WT. Preliminary clinical evaluation of meningococcal disease and bacterial meningitis by ultrasonic enhancement. Arch Dis Child 1998;78:58-60.
14. Cartwright K, Kroll S. Optimising the investigation of meningococcal disease. Br Med J 1997;315:757-8.
15. Cartwright K, Reilly S, White D, Stuart J. Early treatment with parenteral penicillin in meningococcal disease. Br Med J 1992;305:143-7.
16. Nadel S, Levin M, Habibi P. Treatment of meningococcal disease in childhood. In: Cartwright K (ed). Meningococcal disease. Chichester: John Wiley & Sons Ltd, 1995:207-43.
17. Advanced Life Support Group. Relative contraindications to lumbar puncture. In: Advanced paediatric life support - the practical approach. London: BMJ Publishing Group, 1997:127.
18. Rennick G, Shann F, de Campo J. Cerebral herniation during bacterial meningitis in children. Br Med J 1993;306:953-5.
19. Mandl KD, Stack AM, Fleisher GR. Incidence of bacteremia in infants and children with fever and petechiae. J Pediatr 1997;131:398-404.
20. Baker RC, Seguin JH, Leslie N, Gilchrist MJ, Myers MG. Fever and petechiae in children. Pediatrics 1989;84:1051-5.
21. Van Nguyen Q, Nguyen EA, Weiner LB. Incidence of invasive bacterial disease in children with fever and petechiae. Pediatrics 1984;74:77-80.
22. Public Health Laboratory Service Meningococcal Infections Working Group and Public Health Medicine Environmental Group. Control of meningococcal disease: guidance for consultants in communicable disease control. Commun Dis Rep 1995;5: R189-93.
23. Laurichesse H, Grimaud O, Waight P, Johnson AP, et al. Pneumococcal bacteraemia and meningitis in England and Wales, 1993 to 1995. Commun Dis and Public Health 1998;1:22-7.
24. Centers for Disease Control. Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. MMWR 1996;45:1-20.
25. McIntyre PB, Berkey CS, King SM, Schaad UB, et al. Dexamethasone as adjunctive therapy in bacterial meningitis. A meta-analysis of randomized clinical trials since 1988. JAMA 1997;278:925-31.
26. Schaad UB, Kaplan SL, McCracken GH Jr. Steroid therapy for bacterial meningitis. Clin Infect Dis 1995;20:685-90.
27. Nadel S, Derkx B, Hazelzet A, Thomson A, et al. A randomised placebo-controlled, sequential trial to study the efficacy of HA1A human monoclonal antibody in children with meningococcal septic shock. Proceedings of the 1st Annual Meeting of the Royal College of Paediatrics and Child Health. York, 15-19th April 1997.
28. Goldman AP, Kerr SJ, Butt W, Marsh MJ, et al. Extracorporeal support for intractable cardiorespiratory failure due to meningococcal disease. Lancet 1997; 349:466-9.
29. Smith OP, White B, Vaughan D, Rafferty M, et al. Use of protein-C concentrate, heparin and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997;350:1590-3.
30. Best C, Wash J, Sinclair J, Beattie J, et al. Early haemo-diafiltration in meningococcal septicaemia. Lancet 1996;347: 202.
31. Caugant DA, Hoiby EA, Magnus P, Scheel O, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 1994;32:323-30.
32. Meningococcal disease. In: Davies EG, Elliman DAC, Hart CA, Nicoll A, Rudd PT (eds). Manual of childhood infections 1996;2:257-65.
33. Cartwright K. Risk factors for meningococcal disease In: Cartwright K (ed). Meningococcal disease. Chichester: John Wiley and Sons Ltd, 1995:126-38.
34. Cooke RPD, Riordan T, Jones DM, Painter MJ. Secondary cases of meningococcal infection among close family and household contacts in England and Wales, 1984-7. Br Med J 1989;298:555-8.
35. Meningococcal Disease Surveillance Group. Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis 1976;134:201-4.
36. Leach A, Twumasi PA, Kumah S, Banya WS, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus Group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis 1997;175:200-4.
37. Meningococcal. In: Salisbury DM, Begg NT (eds). Immunisation against infectious diseases. London: HMSO, 1996:147-54.
38. Booy R, Hodgson S, Carpenter L, Mayon-White RT, et al. Efficacy of haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994; 344:362-6.
39. Costantino P, Viti S, Podda A, Velmonte MA, et al. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1993;10:691-8.
40. Twumasi PA, Kumah S, Leach A, O'Dempsey TJD, et al. A trial of a Group A plus Group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995;171: 632-8.
41. Anderson EL, Bowers T, Mink CM, Kennedy DJ, et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 1994;62:3391-5.
42. Lieberman JM, Chiu SS, Wong VK, Partridge S, et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. JAMA 1996;275:1499-503.
43. Fairley CK, Begg N, Borrow R, Fox AJ, et al. Conjugate meningococcal A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996;174:1360-3.
44. Borrow R, Fairley CK, Begg N, Fox AJ, et al. Immunogenicity of a meningococcal A and C conjugate vaccine in UK infants. In: Zollinger WD, Frasch CE, Deal CD (eds). Abstracts of the tenth international pathogenic Neisseria conference, Baltimore, MD, 1996:220-1.
45. Frasch CE. Vaccines for prevention of meningococcal disease. Clin Microbiol Rev 1989;2:S134.
46. Sierra GV, Campa HC, Varcacel NM, Garcia IL, et al.. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. Natl Inst Public Health Ann (Oslo) 1991;14:195-207.
47. Boslego J, Garcia J, Cruz C, Zollinger W, et al and the Chilean National Committee for meningococcal disease. Efficacy, safety and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vesicle vaccine in Iquique, Chile. Vaccine 1995:13:821-9.
48. de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340: 1074-8.
49. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case control study. Int J Epidemiol 1995;24:1050-7.
50. Tappero J, Lagos R, Maldonado A, Herrera P, et al. Serum bactericidal activity elicited by two outer membrane protein serogroup B meningococcal vaccines among infants, pre-school children, and adults in Santiago, Chile. In: Zollinger WD, Frasch CE, Deal CD (eds). Abstracts of the tenth international pathogenic Neisseria conference, Baltimore, MD, 1996.
51. Peeters CCAM, Rumke HC, Sundermann LC, Rouppe van der Voort E, et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996;14:1009-15.
52. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
53. Perkins BA, Jonsdottir K, Briem H, Griffiths E, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998;177:683-91.
54. Herbert MA, Heath PT, Mayon-White RT. Meningococcal vaccines for the United Kingdom. Commun Dis Rep 1995;5: R130-5.
55. Hodgetts TJ, Brett A, Castle N. The early management of meningococcal disease. J Accid Emerg Med 1998;15:72-6.